SLC1A4 is a trimeric neutral amino acid transporter essential for shuttling L-serine from astrocytes into neurons. Individuals with biallelic variants in SLC1A4 are known to have spastic tetraplegia, thin corpus callosum, and progressive microcephaly (SPATCCM) syndrome, but individuals with heterozygous variants are not thought to have disease. We identify an 8-year-old patient with global developmental delay, spasticity, epilepsy, and microcephaly who has a de novo heterozygous three amino acid duplication in SLC1A4 (L86_M88dup). We demonstrate that L86_M88dup causes a dominant-negative N-glycosylation defect of SLC1A4, which in turn reduces the plasma membrane localization of SLC1A4 and the transport rate of SLC1A4 for L-serine.

Original languageEnglish
Pages (from-to)1046-1053
Number of pages8
JournalAnnals of Clinical and Translational Neurology
Issue number6
StatePublished - Jun 2023


Dive into the research topics of 'Dominant-negative variant in SLC1A4 causes an autosomal dominant epilepsy syndrome'. Together they form a unique fingerprint.

Cite this